Pancreatic cancer remains one of the most lethal malignancies, with most patients diagnosed after the disease has spread. The five-year survival rate for metastatic cases is only 2–3%, and average survival is often measured in months. Now, UCLA scientists have engineered a new immunotherapy—CAR-NKT cells therapy—that offers fresh hope for this hard-to-treat cancer. Their findings, published in PNAS, show that the therapy can effectively target primary tumors and metastases.
Engineered Off-the-Shelf Cells Target Tumors More Effectively
Led by senior author Dr. Lili Yang, the team designed the therapy using invariant natural killer T (NKT) cells engineered with a CAR that targets mesothelin, a protein commonly found on pancreatic cancer cells. Unlike conventional CAR-T cells, CAR-NKT cells can be mass-produced from donated blood stem cells and stored as off-the-shelf treatments costing approximately $5,000 per dose. This model eliminates the lengthy manufacturing delays associated with personalized cell therapies.
Overcoming Tumor Barriers and Immune Evasion
Pancreatic tumors are notoriously difficult to treat because they develop dense protective barriers and frequently alter their molecular markers. The engineered NKT cells attack through multiple pathways at once, leaving tumors with “no escape routes,” noted first author Dr. Yanruide Li. Even when cancer cells change their signatures to evade detection, the therapy continues attacking from several angles.
Strong Performance in Advanced Preclinical Models
As reported by medicalxpress, the therapy demonstrated potent tumor-homing abilities in rigorous preclinical models that mimic the harsh tumor environments of the pancreas, liver, and lungs. According to study collaborator Dr. Caius Radu, success in these models is especially meaningful because many past treatments have failed after moving to clinical trials. The CAR-NKT cells repeatedly slowed tumor growth, extended survival, and resisted exhaustion across multiple metastatic models.
A Scalable Platform With Broad Cancer Applications
Beyond pancreatic cancer, the therapy may treat mesothelin-expressing tumors such as breast, ovarian, and lung cancers. With preclinical studies completed, the team is preparing FDA applications for clinical testing. Dr. Yang emphasized the urgency: “Pancreatic cancer patients need better options now. Our goal is to bring a potent, safe, scalable, and affordable therapy to the clinic as quickly as possible.”